135 related articles for article (PubMed ID: 21531678)
21. [Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?].
Perey L; Zaman K
Rev Med Suisse; 2007 Oct; 3(130):2406, 2408-10, 2412. PubMed ID: 18062504
[TBL] [Abstract][Full Text] [Related]
22. Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy.
Bardia A; Stearns V
Breast Cancer Res Treat; 2010 Apr; 120(2):437-9. PubMed ID: 20162380
[No Abstract] [Full Text] [Related]
23. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Van Poznak C; Hannon RA; Mackey JR; Campone M; Apffelstaedt JP; Clack G; Barlow D; Makris A; Eastell R
J Clin Oncol; 2010 Feb; 28(6):967-75. PubMed ID: 20065185
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant aromatase inhibitors and bone health.
Chowdhury S; Pickering LM; Ellis PA
J Br Menopause Soc; 2006 Sep; 12(3):97-103. PubMed ID: 16953982
[TBL] [Abstract][Full Text] [Related]
25. Bone health after diagnosis of breast cancer.
Ruzycki SM; Nixon NA
CMAJ; 2018 Dec; 190(49):E1452. PubMed ID: 30530612
[No Abstract] [Full Text] [Related]
26. Effects of third-generation aromatase inhibitors on bone.
McCloskey E
Eur J Cancer; 2006 May; 42(8):1044-51. PubMed ID: 16554149
[TBL] [Abstract][Full Text] [Related]
27. [Diagnosis and treatment of osteoporosis in nonmetastatic breast cancer].
Eiken PA; Hansen M; Kristensen B; Langdahl BL; Abrahamsen B
Ugeskr Laeger; 2011 Feb; 173(8):577-81. PubMed ID: 21333258
[TBL] [Abstract][Full Text] [Related]
28. Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors.
Rachner TD; Göbel A; Jaschke NP; Hofbauer LC
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32674135
[TBL] [Abstract][Full Text] [Related]
29. Toxicity of aromatase inhibitors.
Pandya N; Morris GJ
Semin Oncol; 2006 Dec; 33(6):688-95. PubMed ID: 17145349
[TBL] [Abstract][Full Text] [Related]
30. Aromatase inhibitor agents in breast cancer: evolving practices in hormonal therapy treatment.
Viale PH
Oncol Nurs Forum; 2005 Mar; 32(2):343-53. PubMed ID: 15759071
[TBL] [Abstract][Full Text] [Related]
31. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
Parton M; Smith IE
J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
[No Abstract] [Full Text] [Related]
32. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Hiscox S; Barrett-Lee P; Borley AC; Nicholson RI
Eur J Cancer; 2010 Aug; 46(12):2187-95. PubMed ID: 20471823
[TBL] [Abstract][Full Text] [Related]
33. Adherence to oral endocrine therapy for breast cancer: a nursing perspective.
Miaskowski C; Shockney L; Chlebowski RT
Clin J Oncol Nurs; 2008 Apr; 12(2):213-21. PubMed ID: 18390458
[TBL] [Abstract][Full Text] [Related]
34. Loving our bones.
Sledge GW
Clin Breast Cancer; 2009 May; 9(2):71. PubMed ID: 19433385
[No Abstract] [Full Text] [Related]
35. Bone-Targeted Therapy in Early Breast Cancer.
Jerzak KJ; Raphael J; Desautels DN; Blanchette PS; Tyono I; Pritchard KI
Oncology (Williston Park); 2018 Nov; 32(11):562-9. PubMed ID: 30474104
[TBL] [Abstract][Full Text] [Related]
36. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
37. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Lycette JL; Luoh SW; Beer TM; Deloughery TG
Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073
[TBL] [Abstract][Full Text] [Related]
38. [Effectiveness of adjuvant endocrine therapy for postoperative breast cancer patients].
Doihara H; Ogasawara Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():563-7. PubMed ID: 17682212
[No Abstract] [Full Text] [Related]
39. Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?
Lønning PE
J Clin Oncol; 2008 Oct; 26(30):4859-61. PubMed ID: 18725646
[No Abstract] [Full Text] [Related]
40. Hormone- and chemotherapy-induced bone loss in breast cancer.
Coleman RE
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):16-20. PubMed ID: 15202583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]